Mannitol for Hemodialysis Complications
Trial Summary
What is the purpose of this trial?
This proposal will measure the effects of mannitol administration versus placebo in hypotensive-prone, adult, maintenance hemodialysis patients with respect to changes in patient symptoms and blood pressure stability.
Research Team
Finnian R Mc Causland, MBBCH, MMSc
Principal Investigator
Brigham and Women's Hospital
Eligibility Criteria
This trial is for adults over 18 who are on maintenance hemodialysis for at least 90 days and often have low blood pressure during treatment. They must not be pregnant, planning a kidney transplant soon, or have had a recent heart attack or stroke. Also, they can't join if they're allergic to mannitol or have very high potassium levels.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either hypertonic mannitol or placebo during dialysis sessions to assess effects on blood pressure stability and symptoms
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Mannitol
Mannitol is already approved in United States, European Union, Canada for the following indications:
- Reduction of intracranial pressure
- Promotion of diuresis
- Reduction of intraocular pressure
- Reduction of intracranial pressure
- Treatment of cerebral edema
- Reduction of intracranial pressure
- Promotion of diuresis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor